Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

120.40 -2.81 (-2.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,833,380
Open 122.86
Bid (Size) 119.53 (100)
Ask (Size) 120.50 (800)
Prev. Close 123.21
Today's Range 119.53 - 123.62
52wk Range 88.57 - 128.70
Shares Outstanding 1,253,809,440
Dividend Yield 2.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak ↗
Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead-partnered cancer regimen failed. 
Via Investor's Business Daily
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire

Performance

YTD
+31.0%
+31.0%
1 Month
-2.4%
-2.4%
3 Month
+5.1%
+5.1%
6 Month
+9.5%
+9.5%
1 Year
+30.3%
+30.3%

More News

Read More
News headline image
Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors ↗
Via Chartmill
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study ↗
Via Stocktwits
News headline image
3 Profitable Stocks We Keep Off Our Radar
Via StockStory
News headline image
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
What Does the Market Think About Gilead Sciences Inc? ↗
Via Benzinga
News headline image
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Unpopular Stocks We Think Twice About
Via StockStory
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗
Via MarketBeat
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Top S&P500 movers in Friday's session ↗
Via Chartmill
News headline image
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Gapping S&P500 stocks in Friday's session ↗
Via Chartmill
News headline image
Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Gilead Sciences Inc (NASDAQ:GILD) Demonstrates Strong Dividend Reliability and Profitability ↗
Via Chartmill
News headline image
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
From Gilead Sciences, Inc.
Via Business Wire
News headline image
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Gilead Sciences Inc Chart Analysis ↗
Via Talk Markets
News headline image
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗
Via Benzinga
News headline image
Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 120.40
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 12/12/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 150.96B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 151B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.